XML 22 R10.htm IDEA: XBRL DOCUMENT
v3.24.3

Accrued expenses | 9 Months Ended
--- | ---
Sep. 30, 2024
Payables and Accruals [Abstract] |
Accrued expenses | Accrued expenses Accrued expenses consisted of the following (in thousands):
|  | September 30, |  | December 31,
|  | 2024 |  | 2023
Clinical trial and other development costs |  | $ | 6,414 |  |  | $ | 752 |
Professional fees and general corporate costs |  | 4,463 |  |  | 2,039 |
People related costs |  | 7,266 |  |  | 794 |
Total accrued expenses |  | $ | 18,143 |  |  | $ | 3,585 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration